These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15199290)

  • 41. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
    Guo H; Zhang X; Tang S; Zhang S
    Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lanthanum carbonate: time to abandon prejudices?
    Brancaccio D; Cozzolino M
    Kidney Int; 2007 Feb; 71(3):190-2. PubMed ID: 17252028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The phosphate binder equivalent dose.
    Daugirdas JT; Finn WF; Emmett M; Chertow GM;
    Semin Dial; 2011; 24(1):41-9. PubMed ID: 21338393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new era in phosphate binder therapy: what are the options?
    Salusky IB
    Kidney Int Suppl; 2006 Dec; (105):S10-5. PubMed ID: 17136110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
    Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
    Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
    Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
    Matsuo A; Iida A; Tanimoto M; Matsushita M; Miyamoto K
    Ren Fail; 2014 Sep; 36(8):1291-7. PubMed ID: 24975675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
    Zhai CJ; Yang XW; Sun J; Wang R
    Int Urol Nephrol; 2015 Mar; 47(3):527-35. PubMed ID: 25399356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of efficient phosphate binding on bone in chronic renal failure rats.
    Behets GJ; Gritters M; Dams G; De Broe ME; D'Haese PC
    Ren Fail; 2005; 27(4):475-84. PubMed ID: 16060138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
    Yajima A; Inaba M; Tominaga Y; Tanaka M; Otsubo S; Nitta K; Ito A; Satoh S
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():41-8. PubMed ID: 23586512
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
    Finn WF;
    Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F; Speake M; Hutchison AJ
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lanthanum carbonate.
    Joy MS; Kshirsagar A; Candiani C; Brooks T; Hudson JQ
    Ann Pharmacother; 2006 Feb; 40(2):234-40. PubMed ID: 16449551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.